[Sub-analyses of the DAPA-CKD study: new data on the use of sodium-glucose cotransporter type 2 inhibitor in the treatment of chronic kidney disease]. - Shamkhalova MS; Sukhareva OY; Shestakova MV (Terapevticheskii arkhiv, 2022)